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HALT PKD consists of two ongoing randomized trials with the
largest cohort of systematically studied patients with
autosomal dominant polycystic kidney disease to date. Study
A will compare combined treatment with an angiotensin-
converting inhibitor and receptor blocker to inhibitor alone
and standard compared with low blood pressure targets in
558 early-stage disease patients with an eGFR over 60ml/min
per 1.73m2. Study B will compare inhibitor-blocker treatment
to the inhibitor alone in 486 late-stage patients with eGFR
25–60ml/min per 1.73m2. We used correlation and multiple
regression cross-sectional analyses to determine associations
of baseline parameters with total kidney, liver, or liver cyst
volumes measured by MRI in Study A and eGFR in both
studies. Lower eGFR and higher natural log-transformed
urine albumin excretion were independently associated with
a larger natural log–transformed total kidney volume
adjusted for height (ln(HtTKV)). Higher body surface area was
independently associated with a higher ln(HtTKV) and lower
eGFR. Men had larger height-adjusted total kidney volume
and smaller liver cyst volumes than women. A weak
correlation was found between the ln(HtTKV) and natural
log–transformed total liver volume adjusted for height or
natural log liver cyst volume in women only. Women had
higher urine aldosterone excretion and lower plasma
potassium. Thus, our analysis (1) confirms a strong
association between renal volume and functional
parameters, (2) shows that gender and other factors
differentially affect the development of polycystic disease
in the kidney and liver, and (3) suggests an association
between anthropomorphic measures reflecting prenatal
and/or postnatal growth and disease severity.
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Autosomal dominant polycystic kidney disease (ADPKD)
occurs in 1/400–1/1000 live births and accounts forB4.6% of
the prevalent kidney replacement population in the United
States.1 Hypertension is its most common manifestation and
an important risk factor for its progression to end-stage renal
disease (ESRD) and cardiovascular morbidity and mortality.2
Substantial experimental and clinical data have impli-
cated the renin–angiotensin–aldosterone system (RAAS) in
the pathogenesis of ADPKD and associated hypertension.
However, evidence that treatments targeting the RAAS are
superior to other antihypertensive therapies is inconclusive.
Past studies have been limited by small sample sizes with
inadequate power, short periods of follow-up, study of
relatively late stages of disease, and/or use of low doses of
angiotensin I–converting enzyme inhibitors (ACEIs), which
may not effectively block the RAAS.2
Because of the importance of hypertension in ADPKD and
uncertainties surrounding its treatment, the NIH/NIDDK
funded two distinct multicenter double-blind randomized
clinical trials, adequately powered to assess the effect of
RAAS blockade on renal progression at early (Study A) and
late (Study B) stages of the disease (NCT00283686, http://
clinicaltrials.gov). Their rationale, design, and implementa-
tion have been discussed in detail elsewhere.3
Here we perform a cross-sectional analysis of the baseline
characteristics in this large cohort of patients to identify factors
affecting the development and progression of this disease.
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RESULTS
Baseline patient characteristics
Gender, race, education level, marital status, employment, ages at
the time of enrollment into the study and diagnoses of ADPKD
and hypertension, and manifestations leading to ADPKD and
mode of diagnosis of ADPKD, by study and, in Study A, blood
pressure (BP) target assignment, are shown in Table 1.
The baseline clinical, laboratory, and imaging character-
istics of participants in Studies A and B are shown in Table 2.
Study B participants, who by design have lower estimated
glomerular filtration rate (eGFR) than Study A patients, are
older, have higher body mass index, higher serum concen-
tration of potassium and urine excretion of albumin, and
lower urine excretion of aldosterone and urine sodium/
potassium ratio. Serum potassium concentration is lower in
women in both studies, whereas urine aldosterone excretion
is higher in women compared with men in Study A.
Kidney and liver volumes were measured only in Study A.
Total kidney volume (TKV) and TKV adjusted for height
(HtTKV) or body surface area (BSA) are significantly greater
in men than in women (Table 2). Liver cyst volume (LCV) is
greater in women.
Baseline clinical, laboratory, and imaging characteristics of
participants in Study A by BP group assignment are shown in
Table 3. Except for slightly lower urine aldosterone excretion
in participants assigned to rigorous BP control, there are no
significant differences between the standard and rigorous BP
control groups.
Associations of baseline parameters with kidney volume
Age and natural log–transformed HtTKV, ln(HtTKV), are
significantly correlated in men, but not in women (Table 4).
BSA and height are positively correlated with ln(HtTKV);
these correlations are seen in men but not in women. BSA and
height are also positively correlated with unadjusted lnTKV or
with lnTKV adjusted for BSA (not shown). Office (and home,
not shown) BPs and ln(urine albumin excretion) correlate
positively, whereas eGFR and renal blood flow (RBF) correlate
negatively with ln(HtTKV). Weak positive correlations exist
between urine volume, urine sodium excretion, natural
log–transformed total liver volume adjusted for height and
ln(HtLCV), with ln(HtTKV) in women only.
Multiple regression analysis shows independent associa-
tions of baseline BSA, ln(urine albumin excretion), and eGFR
with baseline ln(HtTKV) (Table 5), unadjusted lnTKV, or
lnTKV adjusted for BSA. The association of BSA with baseline
ln(HtTKV) remains statistically significant if kidney weights
(estimated from TKV) are subtracted from body weights
to calculate BSA, indicating that the association is not due
to a bias introduced by the contribution of kidney volume to
body weight. Body mass index cannot replace BSA in the
model.
Associations of baseline parameters with eGFR
Age, office systolic BP, serum potassium, and ln (urine albu-
min excretion) are negatively correlated, whereas sodium/
potassium ratio is positively correlated with baseline eGFR
(Table 6). BSA, body mass index, office diastolic BP, and urine
potassium excretion are negatively correlated with eGFR in men
only. Urine aldosterone excretion is positively correlated with
eGFR in women only. In Study A, age and ln(HtTKV) are
negatively correlated and RBF is positively correlated with eGFR.
Table 1 | Demographic characteristics of the study population
Study A
(Standard,
n=284)
Study A
(Low,
n=274)
Study B
(n=486)
Gender
Male (n, %) 143 (50.4) 140 (51.2) 235 (48.4)
Race
Caucasian (n, %) 258 (90.9) 259 (94.5) 454 (93.6)
African American (n, %) 7 (2.5) 7 (2.6) 12 (2.5)
Age at enrollment
Years (mean±s.d.) 35.9±8.4 36.5±8.2 48.2±8.3
Educational level
Some high school (n, %) 12 (4.2) 7 (2.6) 2 (0.4)
Completed high school (n, %) 33 (11.6) 31 (11.4) 53 (11.0)
Some college (n, %) 70 (24.7) 57 (21.0) 117 (24.2)
Completed college (n, %) 104 (36.6) 111 (40.8) 160 (33.1)
Graduate studies (n, %) 65 (22.9) 66 (24.3) 152 (31.4)
Marital status
Single (n, %) 82 (29.0) 80 (29.4) 52 (10.7)
Married (n, %) 171 (60.4) 175 (64.3) 363 (74.9)
Divorced/separated (n, %) 27 (9.5) 16 (5.9) 57 (11.8)
Widowed/other (n, %) 3 (1.1) 1 (0.4) 13 (2.6)
Employment
Student (n, %) 25 (8.8) 27 (9.9) 11 (2.3)
Homemaker (n, %) 18 (6.3) 22 (8.0) 43 (8.9)
Part-time employment (n, %) 34 (12.0) 32 (11.7) 50 (10.3)
Full-time employment (n, %) 204 (71.8) 197 (71.9) 342 (70.5)
Other/disabled/retired (n, %) 13 (4.6) 11 (4.0) 60 (12.4)
Diagnosis of ADPKD, age
Years (mean±s.d.) 27.1±9.7 28.0±10.3 33.1±12.3
Diagnosis due to
Screening (n, %) 113 (39.8) 93 (34.2) 184 (37.9)
Incidental imaging (n, %) 37 (13.0) 30 (11.0) 47 (9.7)
Pain (n, %) 42 (14.8) 34 (12.5) 52 (10.7)
Hypertension (n, %) 36 (12.7) 50 (18.4) 69 (14.2)
Routine physical (n, %) 10 (3.5) 8 (2.9) 26 (5.4)
Hematuria (n, %) 15 (5.3) 25 (9.2) 33 (6.8)
UTI (n, %) 5 (1.8) 9 (3.3) 9 (1.9)
Other (n, %) 26 (9.1) 23 (8.5) 65 (13.4)
Diagnosis of ADPKD, mode
Ultrasound (n, %) 205 (72.2) 195 (71.7) 350 (72.2)
CT (n, %) 46 (16.2) 42 (15.4) 54 (11.1)
MRI (n, %) 17 (6.0) 16 (5.9) 23 (4.7)
IVP (n, %) 7 (2.5) 11 (4.0) 31 (6.4)
Other (n, %) 9 (0.1) 8 (0.0) 27 (0.6)
Diagnosis of hypertension, age
Years (mean±s.d.) 30.2±8.7 30.9±9.1 36.2±10.6
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CT, com-
puted tomography; IVP, intravenous pyelogram; MRI, magnetic resonance imaging;
UTI, urinary tract infection.
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Multiple regression analysis shows independent asso-
ciations of baseline age, RBF, and ln(HtTKV) with eGFR
(Table 7). Excluding RBF and ln(HtTKV) from the model, age,
BSA, ln(urine albumin), serum potassium, and urine aldo-
sterone are independently associated with eGFR (Table 7).
Body mass index cannot replace BSA in the model.
DISCUSSION
The HALT PKD A and B populations constitute the largest
cohort of systematically analyzed hypertensive ADPKD
patients published to date. Analysis of the baseline charac-
teristics of the study population demonstrates adequate
randomization between the low and standard BP arms of
Table 2 | Baseline characteristics by gender in Study A and Study B
Study A Study B
Male Female Both Male Female Both
Mean±s.d. (N) Mean±s.d. (N) Mean±s.d. Mean±s.d. (N) Mean±s.d. (N) Mean±s.d.
Age (years) 35.2±8.1 (283) 37.2±8.4** (275) 36.2±8.3 47.4±8.7 (235) 49.0±7.9* (251) 48.2±8.3***
Height (cm) 181.0±7.8 (275) 166.3±7.8*** (271) 173.7±10.7 180.3±8.9 (231) 166.4±20.5*** (246) 173.1±17.4
BSA (m2) 2.1±0.2 (274) 1.8±0.2*** (271) 2.0±0.2 2.1±0.2 (231) 1.8±0.2*** (246) 2.0±0.3
BMI (kg/m2) 27.6±4.7 (274) 27.2±10.4 (271) 27.4±8.0 29.0±5.9 (231) 28.2±12.9 (246) 28.6±10.1*
Office systolic BP (mmHg) 127.2±14.3 (280) 122.9±14.5*** (274) 125.1±14.5 127.9±15.0 (235) 125.4±15.8 (251) 126.6±15.4
Office diastolic BP (mmHg) 80.0±11.4 (280) 78.6±11.8 (274) 79.3±11.6 80.3±9.7 (234) 76.8±10.9*** (251) 78.5±10.5
HtTKV (ml/m) 780.7±419.5 (262) 608.9±367.2*** (266) 694.1±403.0 NA NA NA
RBF (ml/min per 1.73m2) 665.0±224.3 (130) 610.5±205.4* (138) 636.9±216.1 NA NA NA
HtTLV (ml/m) 1114±402 (265) 1137±513 (269) 1126±461 NA NA NA
Liver cyst volume (ml) 146.2±703.0 (226) 343.9±795.6* (241) 248.2±757.9 NA NA NA
eGFR (ml/min per 1.73m2) 90.4±17.8 (282) 92.7±17.1 (275) 91.5±17.5 47.1±11.3 (235) 49.2±12.3 (251) 48.2±11.8***
Serum sodium (mEq/l) 139.3±2.2 (283) 138.6±7.8 (275) 138.9±5.7 138.6±11.8 (234) 139.3±2.4 (249) 138.9±8.4
Serum potassium (mEq/l) 4.2±0.4 (283) 4.0±0.4*** (275) 4.1±0.4 4.3±0.5 (234) 4.2±0.5* (249) 4.3±0.5***
Urine volume (ml) 2639±1201 (272) 2457±1150 (265) 2550±1179 2794±1114 (222) 2541±974* (240) 2662±1050
Urine sodium (mEq/24 h) 194.0±75.3 (254) 161.0±78.5*** (260) 177.3±78.6 202.7±86.6 (211) 153.8±68.1*** (224) 177.5±81.3
Urine potassium (mEq/24 h) 62.9±26.4 (251) 53.5±25.0*** (257) 58.1±26.1 68.7±28.3 (211) 56.3±23.0*** (224) 62.3±26.4*
Urine sodium/potassium ratio 3.5±1.6 (251) 3.3±1.6 (257) 3.4±1.6 3.2±1.2 (211) 3.0±1.5 (224) 3.1±1.3**
Urine aldosterone (mg/24 h) 10.0±5.9 (217) 15.8±12.0*** (223) 12.9±9.9 10.0±7.7 (173) 10.3±7.6 (190) 10.2±7.6***
Urine albumin (mg/24 h) 40.8±73.2 (254) 42.3±183.6 (260) 41.5±140.2 109.1±195.6 (210) 64.9±124.1* (224) 86.3±163.9***
Abbreviations: BMI, body mass index; BP, blood pressure; BSA, body surface area; eGFR, estimated glomerular filtration rate; HtTKV, total kidney volume adjusted for height;
HtTLV, total liver volume adjusted for height; NA, not applicable; RBF, renal blood flow.
Characters in bold indicate statistically significant differences between the genders within Study A and Study B or between Study A and Study B.
*P-valuesp0.05, **p0.005, ***p0.0005.
Table 3 | Baseline characteristics in Study A by blood pressure group assignment
Study A (Standard) Study A (Low)
N Mean±s.d. N Mean±s.d. P-value
Age (years) 284 35.9±8.4 274 36.5±8.2 0.401
Female 284 49.6% 274 48.9% 0.861
Height (cm) 280 173.4±11.5 266 174.0±9.8 0.533
BSA (m2) 279 2.0±0.2 266 2.0±0.2 0.938
BMI (kg/m2) 279 27.8±10.1 266 27.0±5.1 0.225
Office systolic BP (mmHg) 282 125.2±14.6 272 125.0±14.5 0.883
Office diastolic BP (mmHg) 282 79.9±11.7 272 78.7±11.5 0.227
HtTKV (ml/m) 269 704.2±406.1 259 683.7±400.2 0.558
RBF (ml/min per 1.73m2) 131 623.2±215.0 137 650.0±217.2 0.311
HtTLV (ml/m) 273 1128.4±380.4 261 1122.9±532.4 0.892
Liver cyst volume (ml) 241 237.1±596.9 226 260.1±899.6 0.751
eGFR (ml/min per 1.73m2) 283 91.7±17.8 274 91.4±17.2 0.820
Serum sodium (mEq/l) 284 139.1±2.3 274 138.8±7.8 0.572
Serum potassium (mEq/l) 284 4.1±0.4 274 4.1±0.4 0.368
Urine volume (ml) 271 2577±1223 266 2522±1133 0.595
Urine sodium (mEq/24h) 260 176.4±77.7 254 178.2±79.7 0.786
Urine potassium (mEq/24h) 257 57.9±24.4 251 58.4±27.8 0.818
Urine sodium/potassium ratio 257 3.4±1.6 251 3.4±1.6 0.784
Urine aldosterone (mg/24 h) 226 13.9±11.1 214 11.9±8.3 0.033
Urine albumin (mg/24 h) 260 34.9±56.6 254 48.3±191.0 0.284
Abbreviations: BMI, body mass index; BP, blood pressure; BSA, body surface area; eGFR, estimated glomerular filtration rate; HtTKV, total kidney volume adjusted for height;
HtTLV, total liver volume adjusted for height; RBF, renal blood flow.
Characters in bold indicate statistically significant differences.
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Study A. It also identifies novel factors affecting the
development and progression of ADPKD.
Associations of baseline parameters with ln(HtTKV)
Baseline eGFR, ln(urine albumin excretion), and BSA inde-
pendently associate with ln(HtTKV) in the current study.
Previous studies had shown a negative correlation between
TKV and GFR4 and direct associations of TKV with urine
protein and albumin excretions.5 More recently, the Con-
sortium for Radiologic Imaging Studies of Polycystic Kidney
Disease (CRISP) used magnetic resonance imaging (MRI) to
measure TKV annually in a cohort of ADPKD patients with
well-preserved renal function at the initiation of the study.
Age-adjusted TKV was negatively correlated with GFR and
urine albumin excretion at baseline.6 During the initial
CRISP study period of 3 years, TKV was modestly associated
with a decline in GFR measured by iothalamate clearance.7
A more recent CRISP report with 8 years of follow-up has
found increasingly strong associations between baseline
HtTKV and the follow-up iothalamate clearances and
progression through the K/DOQI stages.8 These observations
demonstrate that renal cyst burden, reflected by HtTKV, is a
very important determinant of renal functional decline in
ADPKD.
In the current study, BSA is independently associated with
ln(HtTKV), unadjusted lnTKV, or lnTKV adjusted for BSA.
The association between the anthropomorphic marker BSA
and TKV, even when TKV is adjusted for height or BSA,
points to biological factor or factors associated with, but
distinct from, body size. Genetic and environmental factors
affect birth weights and postnatal growth velocities, which
ultimately determine adult height, weight, and BSA. Gen-
ome-wide association studies have identified loci associated
with height variation.9,10 Associations between height and
risks for particular diseases may reflect common genetic
effects on growth and disease predisposition, rather than
direct associations of phenotypic traits. Low birth weights
increase the risk for insulin resistance, type 2 diabetes,
obesity, and hypertension in adult life,11 whereas high
birth weights are associated with increased risk for various
childhood12–15 and adult16–19 malignancies. Low birth
weights have been associated with lower nephron numbers,
which in turn could increase the risk for hypertension,
proteinuria, and GFR decline in ADPKD, as it has been
reported in other renal diseases.20,21 On the other hand,
enhanced nephrogenesis could accelerate cyst development
as shown in conditional mouse models22–24, and a higher
nephron number could make larger number of cells suscep-
tible to somatic mutations and cyst development in the same
way that a large nephron number and mammary gland
Table 4 | Correlations between ln(htTKV) and other baseline parameters in Study A
ln(htTKV)
Men Women Both
N r-value P-value N r-value P-value N r-value P-value
Age (years) 262 0.233 0.0001 266 0.049 0.4288 528 0.109 0.0121
Height (cm) 262 0.142 0.0215 266 0.075 0.2198 528 0.236 o0.0001
BSA (m2) 261 0.243 o0.0001 266 0.101 0.0998 527 0.275 o0.0001
BMI (kg/m2) 261 0.157 0.0112 266 0.055 0.3675 527 0.084 0.0541
Office systolic BP (mmHg) 261 0.190 0.0020 266 0.106 0.0840 527 0.178 o0.0001
Office diastolic BP (mmHg) 261 0.193 0.0017 266 0.088 0.1533 527 0.152 0.0005
RBF (ml/min per 1.73m2) 128 0.241 0.0062 137 0.169 0.0489 265 0.181 0.0032
eGFR (ml/min per 1.73m2) 262 0.375 o0.0001 266 0.289 o0.0001 528 0.339 o0.0001
Serum sodium (mEq/l) 262 0.043 0.4916 266 0.018 0.7691 528 0.035 0.4184
Serum potassium (mEq/l) 262 0.056 0.3647 266 0.054 0.3765 528 0.044 0.3101
Urine volume (ml) 254 0.042 0.5020 256 0.129 0.0397 510 0.055 0.2156
Urine sodium (mEq/24h) 236 0.044 0.5018 251 0.139 0.0276 487 0.142 0.0017
Urine potassium (mEq/24h) 233 0.027 0.6777 248 0.069 0.2775 481 0.096 0.0351
Urine sodium/potassium ratio 233 0.005 0.9342 248 0.008 0.9054 481 0.015 0.7423
Urine aldosterone (mg/24 h) 201 0.058 0.4135 216 0.017 0.7997 417 0.062 0.2031
ln(Urine albumin) 236 0.286 o0.0001 251 0.446 o0.0001 487 0.360 o0.0001
ln(HtTLV) (in ml/m) 262 0.081 0.1895 262 0.136 0.0264 527 0.112 0.0098
ln(Liver cyst volume) (in ml) 215 0.040 0.5581 233 0.171 0.0088 448 0.066 0.1641
Abbreviations: BMI, body mass index; BP, blood pressure; BSA, body surface area; eGFR, estimated glomerular filtration rate; HtTKV, total kidney volume adjusted for height;
HtTLV, total liver volume adjusted for height; ln(HtTKV), natural log–transformed TKV adjusted for height; ln(HtTLV), natural log–transformed TLV adjusted for height;
RBF, renal blood flow.
Characters in bold indicate statistically significant correlations.
Table 5 | Final regression model to predict ln(HtTKV)
R2=0.287 (n=486)
b-value P-value
BSA (m2) 0.247 o0.001
ln(Urine albumin) (in mg/24 h) 0.324 o0.001
eGFR (ml/min per 1.73m2) 0.286 o0.001
Abbreviations: BSA, body surface area; eGFR, estimated glomerular filtration rate;
HtTKV, total kidney volume adjusted for height; ln(HtTKV), natural log–transformed
TKV adjusted for height.
Characters in bold indicate statistically significant independent predictors.
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mass increase the risk for renal cell and breast cancers.16,25
Postnatal growth may be as important as, or more important
than, prenatal growth for programming pathways predispos-
ing to adult diseases. Faster postnatal growth associated with
high nutrient formula feeding increases the risk for obesity,
insulin resistance, low high-density lipid cholesterol, hyper-
tension, and cardiovascular disease.26–30 As newborns with
low birth weights usually show faster postnatal growth,
whereas large newborns show growth deceleration, it has
been suggested that the association of low birth weight with
higher risk for cardiovascular disease reflects at least in part
the adverse effects of postnatal growth acceleration.28,31–33 At
present, we can only speculate on which genetic and environ-
mental factors affecting growth can also affect the progres-
sion of ADPKD. A large body of evidence, for example,
indicates that the insulin-like growth factor-I system has
a major role in prenatal and postnatal growth34–37 and
mediates epithelial cell proliferation in polycystic kidney
disease.38,39
The fact that the association between BSA and
ln(HtTKV) in the current study is mostly restricted to men
is intriguing but not unique. Gender differences are common
in animal40–43 and human44,45 examples of developmental
programming. Men appear more susceptible to perinatal
programming of metabolic and cardiovascular homeostasis
than women. The associations of birth weight with develop-
ment of chronic kidney disease46–48 and of renal cell cancer16
are stronger in men. Gender differences in hormonal systems
affecting fetal and renal development, such as the insulin-like
growth factor-I37 and the RAS,49 may be responsible for these
gender effects.
Associations of baseline parameters with eGFR
In Study A, age, RBF, and ln(HtTKV) were independently
associated with baseline eGFR. These results are consistent
with those of the CRISP study.50 In Studies A and B, age,
BSA, serum potassium, ln(urine albumin excretion), and
urine aldosterone excretion were independently associated
Table 6 | Correlations between eGFR and other baseline parameters in both studies (A and B)
eGFR
Men Women Both
N r-value P-value N r-value P-value N r-value P-value
Age (years) 517 0.666 o0.0001 526 0.658 o0.0001 1043 0.656 o0.0001
Height (cm) 505 0.019 0.6627 517 0.035 0.4280 1022 0.012 0.7043
BSA (m2) 504 0.147 0.0010 517 0.000 0.9961 1021 0.073 0.0202
BMI (kg/m2) 504 0.188 o0.0001 517 0.026 0.5618 1021 0.072 0.0219
Office systolic BP (mmHg) 514 0.093 0.0360 525 0.093 0.0330 1039 0.095 0.0022
Office diastolic BP (mmHg) 513 0.136 0.0020 525 0.061 0.1621 1038 0.035 0.2571
Serum sodium (mEq/l) 516 0.021 0.6331 524 0.035 0.4214 1040 0.003 0.9228
Serum potassium (mEq/l) 516 0.198 o0.0001 524 0.246 o0.0001 1040 0.223 o0.0001
Urine volume (ml) 494 0.088 0.0506 505 0.070 0.1158 999 0.081 0.0104
Urine sodium (mEq/24h) 465 0.001 0.9881 484 0.050 0.2712 949 0.014 0.6675
Urine potassium (mEq/24h) 462 0.100 0.0311 481 0.063 0.1680 943 0.088 0.0068
Urine sodium/potassium ratio 462 0.178 0.0001 481 0.125 0.0059 943 0.148 o0.0001
Urine aldosterone (mg/24 h) 390 0.003 0.9496 413 0.279 o0.0001 803 0.173 o0.0001
ln(Urine albumin) 464 0.308 o0.0001 484 0.263 o0.0001 948 0.287 o0.0001
Study A 517 0.818 o0.0001 526 0.824 o0.0001 1043 0.820 o0.0001
Abbreviations: BMI, body mass index; BP, blood pressure; BSA, body surface area; eGFR, estimated glomerular filtration rate.
Characters in bold indicate statistically significant correlations.
Table 7 | Final regression models to predict eGFR
Including ln(HtTKV) and RBF Excluding ln(HtTKV) and RBF
R2=0.404 (n=265) R2=0.740 (n=770)
b-value P-value b-value P-value
Age (years) 0.433 o0.001 0.288 o0.001
BSA (m2) — — 0.047 0.012
Serum potassium (mEq/l) — — 0.048 0.013
Urine aldosterone (mg/24 h) — — 0.046 0.015
ln(Urine albumin) (in mg/24 h) — — 0.111 o0.001
ln(HtTKV) (in ml/m) 0.182 o0.001 — —
RBF (ml/min per 1.73m2) 0.300 o0.001 — —
Study A — — 0.606 o0.001
Abbreviations: BSA, body surface area; eGFR, estimated glomerular filtration rate; HtTKV, total kidney volume adjusted for height; ln(HtTKV), natural log–transformed TKV
adjusted for height; RBF, renal blood flow.
Characters in bold indicate statistically significant independent predictors.
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with eGFR. As in the case of ln(HtTKV), the association of
BSA and eGFR is restricted to men. The positive correlation
between urine aldosterone excretion and eGFR and the
lower urinary aldosterone excretion in Study B compared
with Study A participants, despite higher serum potassium
concentrations, suggests that as renal function declines
extracellular fluid volume expansion suppresses the circulat-
ing RAS. In chronic kidney disease, aldosterone production
depends on the extracellular volume status, increases in
response to sodium restriction, and may contribute to renal
disease progression regardless of its level.51–53
Distinct factors affect the severity of polycystic kidney and
liver disease
A number of observations in this study suggest that the
renal involvement in ADPKD may be more severe in men
than in women. In Study A, TKV is significantly greater
in men than in women, even when adjusted by height or
BSA and despite the fact that men are significantly younger
than women. The significant direct correlation between
age and ln(HtTKV) in men, but not in women, may reflect
a higher rate of renal enlargement in men. In Study B,
men have significantly higher BP and urine albumin
excretion than women. The significantly older age of women
in both studies, A and B, probably reflects a selection bias
introduced by the fact that men have more progressive
disease than women and therefore had to be younger at
enrollment into the study in order to meet the eGFR entry
criteria. Nevertheless, we cannot find an independent
association of gender with disease severity reflected by a
higher ln(HtTKV) or a lower eGFR in the multiple regres-
sion analysis. Interestingly, a recent study based on data from
the Danish National Registry on Regular Dialysis and
Transplantation has shown that during 1990–2007 the
mean age of ESRD increased by 5.0 and 4.4 years in
male and female ADPKD patients and that the age-adjusted
male/female ratio at onset of ESRD decreased from 1.6 to
1.1, suggesting that male gender has become less important as
a risk factor for progression in ADPKD in the past two
decades.54
It has been hypothesized that patients with more severe
polycystic kidney disease also have more severe liver involve-
ment, reflecting a higher systemic severity of the disease.55
This was not confirmed by the CRISP study where a
correlation between LCV and TKV became nonsignificant
when adjusted for age.56 The current study detects only a
weak association between ln(HtTKV) and either natural
log–transformed total liver volume adjusted for height or
ln(LCV) in women, but not in men. Furthermore, whereas
men had higher HtTKV than women, women had higher
LCV than men, suggesting opposite sex–linked hormonal
effects on disease progression in polycystic kidneys and
polycystic livers. These observations indicate that, in addition
to the PKD mutations, other factors distinct for each organ
are important for the development and progression of
polycystic kidney and polycystic liver disease.
Gender differences in urine aldosterone excretion and
plasma potassium concentrations
Other observations in this analysis deserve comment. Higher
urine aldosterone excretions in women compared with men
in Study A are consistent with higher serum aldosterone
values in women compared with men and in premenopausal
compared with postmenopausal women in the Framingham
Heart Study.57 Aldosterone production significantly increases
in the luteal phase owing to high progesterone levels58,59
because progesterone is a precursor of aldosterone60,61 and
a mineralocorticoid receptor antagonist with a natriuretic
effect that can activate the RAS.62 Luteinizing hormone may
also stimulate aldosterone synthesis in the adrenal cortex.63
Lower plasma potassium concentrations in women
compared with men have been reported in previous human
and animal studies64–66 and attributed to estrogen effects,
enhancing the action of mineralcorticoids on the kidney and
increasing b2-adrenoreceptor density, affinity, or G protein
coupling to adenylate cyclase in skeletal muscle and red blood
cells, thus causing an intracellular influx of potassium into
the cells.66,67
In summary, a cross-sectional analysis of baseline para-
meters in HALT PKD, the largest cohort of systematically
studied ADPKD patients to date that confirms a strong
association between renal volume and functional parameters,
shows that gender and other factors differentially affect
the development of polycystic disease in the kidney and
liver, and suggests the intriguing possibility that intra-
uterine development and developmental programming
(reflected by BSA and height) affect the natural history of
this disease.
MATERIALS AND METHODS
The design and implementation of the HALT PKD trials have been
described in detail elsewhere.3 The Polycystic Kidney Disease Treat-
ment Network (HALT PKD) includes four participating clinical
centers, three satellite clinical sites, and a coordinating center.
The participating clinical centers include the Emory University,
Mayo Clinic with Kansas University Medical Center and the
Cleveland Clinic, Tufts Medical Center with Beth Israel Deaconess
Medical Center, and University of Colorado Health Sciences.
The Coordinating Center initially at the Washington University is
now at the University of Pittsburgh. HALT PKD began enrolling
subjects in 2006, and concluded enrollment in mid-2009. Follow-up
will continue until 2014.
Organization of the HALT PKD trials
The HALT PKD trials are prospective randomized double-blind
placebo-controlled multicenter interventional trials comparing
treatment with ACEI—angiotensin receptor blocker combination
vs. ACEI alone and standard vs. low BP target in 15- to 49-year-old
ADPKD patients with eGFR 460 ml/min per 1.73 m2 (n¼ 558,
Study A) and ACEI-angiotensin receptor blocker vs. ACEI alone in
18- to 64-year-old patients with eGFR 25–60 ml/min per 1.73 m2
(n¼ 486, Study B). All participants have hypertension or high-
normal BP defined as systolic BP X130 mm Hg and/or diastolic
BP X80 mm Hg on three separate readings within the past year,
or current use of antihypertensive agents for BP control. Standard
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BP control for this study is defined as 120–130/70–80 mm Hg and
low BP as 95–110/60–75 mm Hg.
Washout period and home BP measurements
Participants are trained at the screening visit to perform home BP
measurements at least every other day during the drug washout
period. BP measurements are obtained at least 30 min after
awakening, before eating breakfast, smoking or consuming caffeine,
after sitting for at least 5 min with the arm resting at heart level. The
average of the second and third of three measurements 30 s apart is
used for decision making. If the difference between the two systolic
or diastolic readings is 410 mm Hg, participants record a fourth
and fifth reading and the average of the last four readings is used.
For those patients taking antihypertensive medications, existing
antihypertensives are gradually discontinued and a 2- to 4-week
drug washout period is completed. Labetalol or clonidine is taken
during the washout period for BP control, unless indicated
otherwise. BP drugs taken for non-hypertensive indications are
continued at the discretion of the principal investigator.
Participant baseline visits and randomization procedures
Within 10 weeks of the screening visit, participants return to the
center for a standardized baseline visit including complete history
taking and physical examinations, recording sitting and standing
clinic BP measurements following the same protocol used for home
BP measurements, as well as serum creatinine (see below) and
biochemical measurements, MRI acquisitions in Study A patients,
and completion of 24-h urine collections for determination of
albumin and aldosterone excretion. They also had to complete
health-related questionnaires.
Two blood samples, drawn a minimum of 1-h apart, are sent to the
central laboratory (Cleveland Clinic Foundation Reference Laboratory)
for analysis to establish the baseline serum creatinine measurement.
Consistency of the two serum creatinine measurements (o20%
variation) is required. If the two measurements differ by greater than
20%, a second set of serum creatinine samples is obtained shortly after
and sent for repeat analysis. Glomerular filtration rate is estimated using
the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
equation.68 A 24-hour urine collection is performed for measurements
of sodium, potassium, creatinine, albumin, and aldosterone excretions,
which are carried out at the Diagnostic Laboratory Facility at Brigham
and Women’s Hospital, Boston. Adequacy of the collection is assessed
based on creatinine excretion compared with the predicted value from
lean body weight for age and gender.
MRI is performed in Study A patients for the determination of
TKV, total liver volume, LCV, left ventricular mass, and RBF. MR
images (including RBF images) are obtained at each center using a
protocol developed by the HALT PKD Imaging Subcommittee.
Following acquisition, MR images are reviewed locally and then
transferred electronically to the Image Analysis Center at the
University of Pittsburgh. The cardiac MR imaging results will be
reported separately.
Randomization procedures
Randomization was performed by the coordinating center at the
baseline visit in equal proportions to combined lisinopril plus
telmisartan or lisinopril plus placebo using random permuted
blocks with stratification by center, participant age, gender, race, and
baseline eGFR. Study A patients were additionally randomized in
equal proportions to either a standard BP (120–130/70–80 mm Hg)
or low BP (95–110/60–75 mm Hg) target.
Statistical methods
The data were analyzed using STATA/SE 11.1 (College Station, TX).
Group comparisons were conducted using two-sample t-tests,
and correlations were reported using Pearson’s correlation coeffi-
cients. The comparison of categorical variables across groups
was conducted using w2-tests. Continuous data were investigated
for violations of normality, as well as outliers. In the event that
these violations occurred, suitable transformations were taken
(i.e., natural logarithm).
Multiple regression models were built to examine how clinical
and laboratory baseline variables were associated with baseline TKV
or eGFR. Predictor variables for each of the initial multivariate
models were chosen based on significant (Po0.10) univariate
correlations with the respective outcome. The predictor variables
were also checked for multicollinearity using variance inflation
factors. Stepwise selection, with probabilities to enter and remove as
0.05 and 0.10, respectively, was used for model building. Only
variables with Po0.05 were further considered for the final models.
Finally, standardized regression coefficients were used to facilitate
the comparison of predictor variables. Standardized regression
coefficients were calculated within STATA11 as follows: bstd¼
bunstd[Sx/Sy], where bunstd is the unstandardized coefficient from a
multiple regression model, and Sx and Sy are the standard deviations
for the covariate of interest and the outcome variable, respectively.
Because of the exploratory nature of the analyses, adjustments for
multiplicity were not performed.
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